CDSCO Orders Nationwide Crackdown on Unauthorised GLP-1 Weight Loss Drugs

The Central Drugs Standard Control Organization (CDSCO), operating under the Directorate General of Health Services, Government of India, has issued a sweeping directive to all State and Union Territory Drug Controllers, calling for urgent and coordinated enforcement action against the unauthorized promotion and distribution of GLP-1-based weight loss drugs across the country.

The directive, signed by Dr. Rajeev Singh Raghuvanshi, Drugs Controller General of India, and dated 27 March 2026, follows several weeks of intensive field operations conducted jointly by CDSCO and State Licensing Authorities (SLAs). These operations targeted illegal distribution networks, non-compliant dispensing practices, and the rampant misuse of GLP-1-receptor agonists — a class of drugs originally developed for managing type 2 diabetes but increasingly misused off-label for weight management.

Raids, Inspections & Notices Issued

As part of the nationwide enforcement drive, audits and inspections were carried out at a wide range of establishments — spanning online pharmacy warehouses, drug wholesalers, retail pharmacies, and wellness and slimming clinics. Entities found in breach of labelling requirements or approval conditions have been served with formal notices. A press release was publicly issued on 24 March 2026, signalling the government’s intent to publicly hold violators accountable.

End-to-End Supply Chain Monitoring Mandated

The circular places particular emphasis on end-to-end supply chain integrity for GLP-1-based drugs. State and UT Drug Controllers have been explicitly directed to ensure that manufacture, import, wholesale, retail, and dispensing of these drugs occur exclusively through authorized channels and strictly in line with approved indications and labelling conditions. The regulator has made clear that any leakage into unauthorized channels or diversion of supply will attract serious regulatory consequences.

The directive comes amid growing concerns about the social-media-fuelled popularity of drugs such as semaglutide and liraglutide in India, where demand for quick-fix obesity solutions has created fertile ground for unregulated supply chains — including grey-market imports, spurious products, and prescription-free dispensing at unlicensed clinics.

Advertising Watchdog Coordination Called For

Beyond physical supply chains, the circular directs Drug Controllers to actively monitor print, electronic, digital, social media, and outdoor platforms for non-compliant advertisements or surrogate promotional activities for these drugs. Enforcement action is to be initiated under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, and the Drugs and Cosmetics Act, 1940.

Where necessary, CDSCO has encouraged State authorities to coordinate with the Advertising Standards Council of India (ASCI) and other relevant agencies to strengthen the enforcement ecosystem. This reflects a recognition that digital platforms have become the primary vectors for misleading and illegal drug promotion in India today.

Industry Stakeholder Advisories to Follow

Drug Controllers in each state and union territory have also been asked to issue formal advisories to industry stakeholders within their jurisdictions, ensuring awareness and compliance with the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, the Drugs and Cosmetics Act, 1940, and all guidelines previously issued by CDSCO. Copies of the circular have been forwarded to all CDSCO Zonal and Sub-zonal offices for immediate action.

The enforcement push marks one of the most wide-ranging interventions by Indian drug authorities in the rapidly evolving landscape of weight-management therapeutics, and signals that regulators are increasingly alert to the public health risks posed by uncontrolled proliferation of potent prescription drugs outside legitimate medical supervision.